MCTP Bought Genomatix NextGen Sequencing Analysis Stations
News Apr 01, 2009
Genomatix Software announced that the Michigan Center for Translational Pathology (MCTP) at the University of Michigan installed a Genomatix Mining Station (GMS) and a Genomatix Genome Analyzer (GGA) at its labs in Ann Arbor, MI. GMS and GGA are a combination of purpose built high performance hardware and terabytes of proprietary database and software technology combined to provide a turnkey solution for the analysis of NGS data. Together they represent the only complete, integrated analysis solution for NGS data, starting with the raw data generated by the sequencer, leading to a molecular level understanding of the biology being studied.
Peter Grant, Chief Executive Officer at Genomatix, USA commented: "Placing our systems in these highly acclaimed labs at the University of Michigan makes us very proud, and confirms that Genomatix' technology is clearly at the leading edge of this important new genomic technology... right in step with the research that is being done here. We have more than a decade of research and development behind many of the tools implemented in this sweeping array of analysis applications, a fact that places us at the very forefront of the NGS data analysis market. We are prepared today for the data avalanche that will inevitably come from the 'next'-next generation of sequencers."
The MCTP was formed in 2005, under the directorship of Dr. Arul Chinnaiyan, M.D., Ph.D.and Howard Hughes Medical Investigator, as a focused initiative to bring research discoveries from molecular medicine to practical, clinical applications for the identification of biomarkers and therapeutic targets for cancers of the prostate, breast, lung, colon, and skin, as well as other diseases. MCTP utilizes innovative "omics" approaches, cutting-edge high-throughput genomic screening, along with novel bioinformatics and computational analysis to search the human genomes of patients for abnormalities. They comprehensively examine disease development from the foundations of genetic abnormality up through whole body systems, to gain a more integrated, complete insight into the origins of disease.
The Genomatix Mining Station is the first level analysis solution starting at the raw data from the sequencer, delivering ultra fast mapping, SNP detection, expression profiling and splice analysis. Copy number analysis, small RNA analysis and de-novo assembly are following shortly. Results seamlessly feed into second level analysis with the Genomatix Genome Analyzer which puts them into broad biological context, annotates, integrates and visualizes. Clustering, pattern detection, deep transcription factor analysis, phylogeny, correlation and meta-analysis, pathway and network mining are done by the GGA.
Genomatix Software GmbH is a computational biology company headquartered in Munich, Germany with a seat of business in Ann Arbor, MI, U.S.A. Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation. Over a decade of developments in computational and systems biology has put Genomatix into position to have a complete analysis pipeline in place at the arrival of next generation sequencing technology. Genomatix has published more than 180 peer reviewed scientific papers with more than 5,000 citations. Over 35,000 researchers worldwide currently apply Genomatix tools and databases.
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Targeting a Leaky Protein that Causes ParalysisNews
A rare genetic disorder in which people are overcome suddenly with profound muscle weakness is caused by a hole in a membrane protein that allows sodium ions to leak across cell membranes. Compounds containing a chemical group called guanidinium can block the pore created by the mutation and stop the sodium leak without altering the voltage sensor’s ability to function.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018